Stay updated on Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    Removed the reference to the 2012 NEJM article Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. This background citation supported contextual information but is not part of the study's design, results, or eligibility details.
    Difference
    0.1%
    Check dated 2026-08-01T22:55:40.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The page shows a new revision tag v3.6.4 replacing the previous v3.6.3, indicating a minor patch or update to the page or system without visible content changes.
    Difference
    0.1%
    Check dated 2026-07-25T16:59:28.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    No Change Detected
  5. Check
    31 days ago
    Change Detected
    Summary
    The page’s revision indicator was updated to v3.6.3, indicating a minor site update. This does not modify the study details or related data.
    Difference
    0.1%
    Check dated 2026-07-04T04:25:38.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    A classic NEJM trial reference on preoperative chemotherapy plus surgery for NSCLC was added, and the site revision tag was updated from v3.6.0 to v3.6.2.
    Difference
    0.1%
    Check dated 2026-06-27T03:05:41.000Z thumbnail image
  7. Check
    45 days ago
    Change Detected
    Summary
    Adds a literature citation for pembrolizumab in non-small-cell lung cancer (N Engl J Med. 2015;372:2018-2028) to provide background context for the drug's use in NSCLC.
    Difference
    0.1%
    Check dated 2026-06-19T22:09:26.000Z thumbnail image
  8. Check
    52 days ago
    Change Detected
    Summary
    The study record adds a named contact entry (Myung-Ju Ahn) and new help/navigation links (How to Read a Study Record, Common Questions, How to Join a Study), and adjusts the Intervention/Treatment label and related status wording.
    Difference
    1%
    Check dated 2026-06-12T16:30:21.000Z thumbnail image

Stay in the know with updates to Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.